Search Protocols under revision. Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseAcute Lymphoblastic LeukaemiaNHL, T-cell typeNHL, T-Cell Type, Adult T-Cell Leukemia or LymphomaNHL, T-Cell Type, Anaplastic Large CellNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupCD30+HTLV-1-associatedT-ALLICD10C84.4C84.5C84.6C84.7C86.1C86.2C86.5C91.0-C91.5-MeSHLeukemia-Lymphoma, Adult T-CellLymphoma, Primary Cutaneous Anaplastic Large CellLymphoma, T-CellLymphoma, T-Cell, PeripheralSequenceT-ALL: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375, ALL/NHL, C1 (PID2061) -|- C2 (PID2064) -|- C3 (PID2061) -|- C4 (PID2064) -|- C4N (PID2083) -|- C5 (PID2063) -|- C5N (PID2083) -|- C6 (PID2065) -|- C7 (PID2063) -|- C8 (PID2065) -|- Month 1-5 (PID2072) -|- Month 6 (PID2083) -|- Month 7 (PID2083) -|- Month 8-17 (PID2072) -|- Month 18 (PID2074) -|- Month 19 (PID2061) -|- Month 20-30 (PID2072)ChemotherapyChemo-substanceBrentuximab vedotinCarboplatinCyclophosphamideDoxorubicinEtoposideIfosfamideInterferon alpha-2a pegylatedNelarabinePeg asparaginasePrednisoloneZidovudineChemo-substanceBrentuximab vedotinCarboplatinCyclophosphamideDoxorubicinEtoposideIfosfamideInterferon alpha-2a pegylatedNelarabinePeg asparaginasePrednisoloneZidovudineChemo-substanceBrentuximab vedotinCarboplatinCyclophosphamideDoxorubicinEtoposideIfosfamideInterferon alpha-2a pegylatedNelarabinePeg asparaginasePrednisoloneZidovudineChemo-substanceBrentuximab vedotinCarboplatinCyclophosphamideDoxorubicinEtoposideIfosfamideInterferon alpha-2a pegylatedNelarabinePeg asparaginasePrednisoloneZidovudineNo. Substances24 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMesnaParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMesnaParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMesnaParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMesnaParacetamolPegfilgrastimNo. Substances46Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseMaintenanceTherapy intentioncurativedisease controlpalliativeRisksAnemia Hb below 8g/dlDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaInfectionsNeuropathyNeutropeniaPyrexiaThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorGill PSHorwitz SRausch CRVan de Wyngaert ZDiseaseAdulte T-Zell Leukämie oder Lymphom, HTLV-1-assoziiertHochmaligne B-ALL/T-ALL und Burkitt-Lymphom bei Erwachsenen, Erstlinieperipheres T-Zell Lymphom, CD30+, Erstlinie, ECOG 0-2rezidiviertes oder refraktäres peripheres T-Zell Lymphom, CD30+, ECOG 0-3OriginDepartment of Internal Medicine, University of Southern California School of Medicine, Los Angeles, USADivision of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TexasHématologie clinique et thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, FranceMemorial Sloan Kettering Cancer Center, New York, ECHELON-2 study groupProtocols in Revision 4 protocols foundBV-ICE - Brentuximab Vedotin 1.8 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, T-cell Lymphoma (PID2420 V1.0)Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma (PID1204 V1.0)Nelarabine 650 / Peg-asparaginase 1500, T-ALL, maintenance, month 6, 7 (PID2083 V1.1)Peginterferon alpha-2a 90 / zidovudine 200, T-cell Lymphoma (PID3120 V1.0)
